GB9311281D0
(en)
*
|
1993-06-01 |
1993-07-21 |
Rhone Poulenc Rorer Ltd |
Novel composition of matter
|
US5698711A
(en)
|
1991-01-28 |
1997-12-16 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
|
US6096768A
(en)
*
|
1992-01-28 |
2000-08-01 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
|
AU6526896A
(en)
*
|
1995-07-22 |
1997-02-18 |
Rhone-Poulenc Rorer Limited |
Substituted aromatic compounds and their pharmaceutical use
|
JP4309475B2
(ja)
*
|
1996-08-19 |
2009-08-05 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のベンゾフラン―4―カルボキサミド
|
JP2001504457A
(ja)
*
|
1996-11-01 |
2001-04-03 |
ニトロメド インコーポレーテッド |
ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
|
US5958926A
(en)
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
USRE37234E1
(en)
*
|
1996-11-01 |
2001-06-19 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
|
US5874437A
(en)
*
|
1996-11-01 |
1999-02-23 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
KR100640025B1
(ko)
|
1997-02-17 |
2006-10-31 |
알타나 파마 아게 |
3-(시클로프로필메톡시)-n-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물
|
US6472425B1
(en)
|
1997-10-31 |
2002-10-29 |
Nitromed, Inc. |
Methods for treating female sexual dysfunctions
|
US6172118B1
(en)
*
|
1998-04-14 |
2001-01-09 |
Smithkline Beecham Corporation |
Compounds
|
AU3284000A
(en)
*
|
1999-03-10 |
2000-09-28 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis
|
US6653309B1
(en)
|
1999-04-26 |
2003-11-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of IMPDH enzyme technical field of the invention
|
PT1176960E
(pt)
*
|
1999-05-04 |
2005-02-28 |
Altana Pharma Ag |
Combinacao sinergica compreendendo roflumilast e um inibidor de pde-3
|
DK1212089T3
(da)
*
|
1999-08-21 |
2006-07-24 |
Altana Pharma Ag |
Synergistisk kombination af Roflumilast og Salmeterol
|
JP2003534328A
(ja)
|
2000-05-25 |
2003-11-18 |
メルク フロスト カナダ アンド カンパニー |
フルオロアルコキシ置換ベンズアミドジクロロピリジニルn−オキシドpde4阻害剤
|
DE10043074A1
(de)
*
|
2000-09-01 |
2002-03-14 |
Aventis Cropscience Gmbh |
Herbizid wirksame Benzoylcyclohexandione
|
EP1188438A1
(en)
*
|
2000-09-15 |
2002-03-20 |
Warner-Lambert Company |
Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
|
EP1199074A1
(en)
*
|
2000-09-15 |
2002-04-24 |
Warner-Lambert Company |
Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
|
AU2002227123A1
(en)
*
|
2000-11-07 |
2002-05-21 |
Merck And Co., Inc. |
Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
|
US20100310477A1
(en)
*
|
2000-11-28 |
2010-12-09 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg. |
Pharmaceutical compositions based on anticholingerics and additional active ingredients
|
US6699890B2
(en)
|
2000-12-22 |
2004-03-02 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7205320B2
(en)
*
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
EP1397359B1
(en)
|
2001-05-24 |
2005-08-31 |
Merck Frosst Canada & Co. |
1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
|
HUP0401963A3
(en)
*
|
2001-08-09 |
2006-01-30 |
Ono Pharmaceutical Co |
Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
|
DE10207160A1
(de)
*
|
2002-02-20 |
2003-12-18 |
Altana Pharma Ag |
Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
|
MY140561A
(en)
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
TWI347845B
(en)
*
|
2002-03-06 |
2011-09-01 |
Nycomed Gmbh |
Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
|
WO2003094967A2
(en)
*
|
2002-05-07 |
2003-11-20 |
Altana Pharma Ag |
New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
|
CA2484276A1
(en)
*
|
2002-05-07 |
2003-11-20 |
Altana Pharma Ag |
Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
|
AU2003232148A1
(en)
*
|
2002-05-16 |
2003-12-02 |
Pharmacia Corporation |
A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
|
DK2020243T3
(en)
*
|
2002-05-28 |
2018-11-19 |
Astrazeneca Ab |
Pharmaceutical composition which can be applied topically
|
MXPA05000827A
(es)
|
2002-07-19 |
2005-08-29 |
Memory Pharm Corp |
Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
|
CN100381425C
(zh)
|
2002-07-19 |
2008-04-16 |
记忆药物公司 |
作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑及其药物组合物和用途
|
AU2003263393A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Glenmark Pharmaceuticals Limited |
New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
|
AU2003288901A1
(en)
*
|
2002-09-06 |
2004-03-29 |
Merck And Co., Inc. |
Treatment of rheumatoid arthritis by inhibition of pde4
|
CA2497977A1
(en)
|
2002-09-20 |
2004-04-01 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
US6822114B1
(en)
|
2002-10-08 |
2004-11-23 |
Albemarle Corporation |
Process for production of fluoroalkoxy-substituted benzamides and their intermediates
|
AP2021A
(en)
|
2002-10-23 |
2009-08-03 |
Glenmark Pharmaceuticals Ltd |
Novel tricyclic compounds useful for the treatmentof inflammatory and allergic disorders: Process f or their preparation and pharmaceutical compositions containing them
|
DE60334243D1
(de)
*
|
2002-11-19 |
2010-10-28 |
Memory Pharmaceutical Corp |
Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
|
DE60321953D1
(de)
*
|
2002-11-27 |
2008-08-14 |
Nycomed Gmbh |
Neue synergistische zusammensetzung enthaltend roflumilast und formoterol
|
WO2004067006A1
(en)
*
|
2003-01-27 |
2004-08-12 |
Pharmacia Corporation |
Combination of a pde iv inhibitor and a tnf-alpha antagonist
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1606261B1
(en)
*
|
2003-03-10 |
2009-11-04 |
Nycomed GmbH |
Novel process for the preparation of roflumilast
|
EP1624893A2
(en)
|
2003-04-01 |
2006-02-15 |
Applied Research Systems ARS Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
CN1829711B
(zh)
|
2003-04-11 |
2010-06-16 |
格兰马克药品股份有限公司 |
用于治疗炎性和过敏性病症的新杂环化合物、其制备方法和含有它们的药物组合物
|
DE10318610A1
(de)
*
|
2003-04-24 |
2004-11-11 |
Elbion Ag |
7-Azaindole und deren Verwendung als Therapeutika
|
WO2004098596A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising roflumilast and il-1 trap
|
WO2004098598A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
|
WO2004098595A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
|
WO2004098597A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising roflumilast and shuil-1r ii
|
EP1628682B1
(en)
|
2003-05-22 |
2013-09-25 |
Takeda GmbH |
Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd
|
US7923467B2
(en)
*
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
EP1663999A2
(en)
*
|
2003-08-29 |
2006-06-07 |
Ranbaxy Laboratories, Ltd. |
Inhibitors of phosphodiesterase type-iv
|
CA2537230A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Altana Pharma Ag |
Use of pde4 inhibitors for the treatment of diabetes mellitus
|
WO2005026095A1
(en)
*
|
2003-09-12 |
2005-03-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of roflumilast
|
WO2005046676A1
(en)
*
|
2003-11-12 |
2005-05-26 |
University Of South Carolina |
Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
|
EP1685849B1
(en)
|
2003-11-20 |
2012-01-25 |
Astellas Pharma Inc. |
Pde 4 inhibitors for the treatment of interstitial cystitis
|
EP1694655A2
(en)
*
|
2003-11-26 |
2006-08-30 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
MY141255A
(en)
*
|
2003-12-11 |
2010-03-31 |
Memory Pharm Corp |
Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
|
JP4819699B2
(ja)
*
|
2004-02-06 |
2011-11-24 |
メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト |
喘息及びcopdの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤
|
NZ548301A
(en)
*
|
2004-02-06 |
2010-07-30 |
Meda Pharma Gmbh & Co Kg |
Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
|
EP1720835B1
(en)
|
2004-02-18 |
2012-12-12 |
Nycomed GmbH |
Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
|
US20070167496A1
(en)
*
|
2004-02-27 |
2007-07-19 |
Attana Pharma Ag |
Roflumilast and glycopyrronium combination
|
ES2505473T3
(es)
|
2004-03-03 |
2014-10-10 |
Takeda Gmbh |
Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la PDE4
|
WO2006006740A1
(ja)
*
|
2004-07-14 |
2006-01-19 |
Japan Tobacco Inc. |
3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤
|
JP4018739B2
(ja)
|
2004-07-15 |
2007-12-05 |
日本たばこ産業株式会社 |
縮合ベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤
|
US20080009535A1
(en)
*
|
2004-08-30 |
2008-01-10 |
Sarala Balachandran |
Inhibitors of phosphodiesterase type-IV
|
DE102004046235A1
(de)
|
2004-09-22 |
2006-03-30 |
Altana Pharma Ag |
Arzneimittelzubereitung
|
DE102004046236A1
(de)
*
|
2004-09-22 |
2006-03-30 |
Altana Pharma Ag |
Arzneimittelzubereitung
|
US20080085858A1
(en)
*
|
2004-10-13 |
2008-04-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Pharmaceutical Composition
|
US20070287689A1
(en)
*
|
2004-10-13 |
2007-12-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
|
CA2583497A1
(en)
|
2004-10-13 |
2006-04-20 |
Glenmark Pharmaceuticals S.A. |
Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
|
KR101317119B1
(ko)
|
2004-12-17 |
2013-10-11 |
그렌마크 파머수티칼스 에스. 아. |
염증성 및 알레르기성 장애의 치료에 유용한 신규한헤테로사이클릭 화합물
|
SI1831227T1
(sl)
|
2004-12-17 |
2013-09-30 |
Glenmark Pharmaceuticals S.A. |
Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
|
WO2006094640A2
(en)
*
|
2005-03-04 |
2006-09-14 |
F.Hoffmann-La Roche Ag |
Roflumilast and integrin inhibitor combination and method of treatment
|
WO2006094942A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Nycomed Gmbh |
Roflumilast for the treatment of diabetes mellitus
|
CN102600144A
(zh)
|
2005-03-08 |
2012-07-25 |
奈科明有限责任公司 |
治疗糖尿病的罗氟司特
|
JP4991693B2
(ja)
*
|
2005-03-16 |
2012-08-01 |
メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
|
JP5383183B2
(ja)
|
2005-03-16 |
2014-01-08 |
タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ロフルミラストを含有する矯味された剤形
|
SI2366393T1
(sl)
|
2005-04-19 |
2013-12-31 |
Takeda Gmbh |
Roflumilast za zdravljenje pljučne hipertenzije
|
CA2607331A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Nycomed Gmbh |
Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
|
WO2006132342A1
(ja)
*
|
2005-06-09 |
2006-12-14 |
Santen Pharmaceutical Co., Ltd. |
ロフルミラスト点眼液
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
JP2009514851A
(ja)
*
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
RU2465915C2
(ru)
|
2005-12-21 |
2012-11-10 |
Меда Фарма Гмбх Унд Ко. Кг |
Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
|
US7906508B2
(en)
|
2005-12-28 |
2011-03-15 |
Japan Tobacco Inc. |
3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
|
US7863446B2
(en)
*
|
2006-01-19 |
2011-01-04 |
Orchid Research Laboratories Limited |
Heterocycles
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CL2007000667A1
(es)
*
|
2006-03-14 |
2008-03-14 |
Ranbaxi Lab Ltd |
Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
MX2008016123A
(es)
|
2006-07-05 |
2009-01-15 |
Nycomed Gmbh |
Combinacion de inhibidores de reductasa hmg-coa con inhibidores de fosfodiesterasa 4 para el tratamiento de enfermedades inflamatorias pulmonares.
|
RU2009105089A
(ru)
*
|
2006-07-14 |
2010-08-27 |
Ранбакси Лабораториз Лимитед (In) |
ПОЛИМОРФНЫЕ ФОРМЫ ГМГ-КоА-РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ
|
EP2058310A4
(en)
|
2006-09-01 |
2010-11-17 |
Kyorin Seiyaku Kk |
PYRAZOLOPYRIDINCARBOXYL ACID AMID DERIVATIVE AND THE DERIVATIVELY PHOSPHODIESTERASE (PDE) INHIBITOR
|
US7998971B2
(en)
*
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008035316A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
US20080221103A1
(en)
*
|
2007-03-09 |
2008-09-11 |
Orchid Research Laboratories Ltd. |
New heterocyclic compounds
|
KR100844125B1
(ko)
*
|
2007-03-23 |
2008-07-04 |
한국화학연구원 |
7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-a]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
|
BRPI0811214A2
(pt)
|
2007-05-16 |
2014-10-29 |
Nycomed Gmbh |
Derivados de pirazolona
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA3089569C
(en)
|
2007-06-04 |
2023-12-05 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
JP5240205B2
(ja)
|
2008-01-11 |
2013-07-17 |
アステラス製薬株式会社 |
精巣の疼痛又は不快感行動及び頻尿併発モデル動物
|
CA2715069C
(en)
|
2008-02-01 |
2016-06-07 |
Orchid Research Laboratories Limited |
Novel heterocycles
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
US20100029689A1
(en)
*
|
2008-07-02 |
2010-02-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2216327A1
(en)
*
|
2009-02-06 |
2010-08-11 |
CHIESI FARMACEUTICI S.p.A. |
Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
AU2011253203A1
(en)
|
2010-05-10 |
2012-11-22 |
Gilead Sciences, Inc. |
Bifunctional quinoline derivatives
|
US8367829B2
(en)
|
2010-05-10 |
2013-02-05 |
Gilead Sciences, Inc. |
Bi-functional pyrazolopyridine compounds
|
TR201909709T4
(tr)
*
|
2010-06-24 |
2019-07-22 |
Leo Pharma As |
Fosfordiesteraz inhibitörleri olarak benzodioksol türevleri.
|
CN102311382B
(zh)
*
|
2010-06-29 |
2014-05-21 |
大道隆达(北京)医药科技发展有限公司 |
罗氟司特的晶态及其制备方法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN102093194B
(zh)
*
|
2010-12-24 |
2014-01-08 |
江苏先声药物研究有限公司 |
3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
|
CN102617457A
(zh)
*
|
2011-01-28 |
2012-08-01 |
天津药物研究院 |
一种制备罗氟司特的新方法
|
CA2828346C
(en)
|
2011-03-01 |
2021-01-26 |
Synergy Pharmaceuticals Inc. |
Process of preparing guanylate cyclase c agonists
|
CN102690194B
(zh)
*
|
2011-03-24 |
2014-06-25 |
上海通远生物科技有限公司 |
3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
|
CN102775345A
(zh)
*
|
2011-05-13 |
2012-11-14 |
上海特化医药科技有限公司 |
制备罗氟司特的方法及中间体
|
CN102276522B
(zh)
*
|
2011-06-15 |
2013-04-17 |
无锡泓兴生物医药科技有限公司 |
一种制备罗氟司特的方法及其中间体
|
CN102336703B
(zh)
*
|
2011-07-20 |
2013-09-25 |
华润赛科药业有限责任公司 |
一种制备罗氟司特的方法
|
CN102351787B
(zh)
*
|
2011-08-18 |
2014-08-13 |
天津市汉康医药生物技术有限公司 |
高生物利用度的罗氟司特化合物
|
WO2013030789A1
(en)
|
2011-08-30 |
2013-03-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
|
CN102336704B
(zh)
*
|
2011-10-19 |
2013-04-17 |
丁克 |
一种制备罗氟司特的方法
|
KR20140078719A
(ko)
*
|
2011-10-21 |
2014-06-25 |
키에시 파르마슈티시 엣스. 피. 에이. |
포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
|
CN102336705B
(zh)
*
|
2011-10-28 |
2013-03-27 |
成都苑东药业有限公司 |
一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
|
CA2855021A1
(en)
|
2011-11-09 |
2013-05-23 |
Mylan Laboratories Ltd |
Process for the preparation of roflumilast
|
WO2013081565A1
(en)
|
2011-11-21 |
2013-06-06 |
Mahmut Bilgic |
Pharmaceutical compositions comprising roflumilast and terbutaline
|
WO2013077830A1
(en)
|
2011-11-25 |
2013-05-30 |
Mahmut Bilgic |
Synergistilly active combinations of roflumilast and carmoterol
|
WO2013084182A1
(en)
|
2011-12-08 |
2013-06-13 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
|
CN102603623A
(zh)
*
|
2011-12-26 |
2012-07-25 |
北京赛林泰医药技术有限公司 |
制备高纯度罗氟司特的方法
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
WO2013131255A1
(en)
|
2012-03-07 |
2013-09-12 |
Scinopharm (Changshu) Pharmaceutical, Ltd. |
Preparation method of roflumilast
|
WO2014012954A1
(en)
|
2012-07-18 |
2014-01-23 |
Takeda Gmbh |
Treatment of partly controlled or uncontrolled severe asthma
|
CN103630613B
(zh)
*
|
2012-08-21 |
2015-08-05 |
北大方正集团有限公司 |
分离并检测罗氟司特及其中间体的方法
|
WO2014060464A1
(en)
|
2012-10-17 |
2014-04-24 |
Interquim, S.A. |
Process for preparing roflumilast
|
CN110464724A
(zh)
*
|
2013-01-28 |
2019-11-19 |
理森制药股份公司 |
通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
|
JP6307525B2
(ja)
|
2013-02-04 |
2018-04-04 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
新規の置換縮合ピリミジン化合物
|
WO2014117947A1
(en)
|
2013-02-04 |
2014-08-07 |
Grünenthal GmbH |
4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
|
US9545446B2
(en)
|
2013-02-25 |
2017-01-17 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
TW201512189A
(zh)
|
2013-04-16 |
2015-04-01 |
Gruenenthal Chemie |
新型被取代之嘧啶縮合化合物
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
CN103304475A
(zh)
*
|
2013-06-13 |
2013-09-18 |
湖南千金湘江药业股份有限公司 |
苯甲酰胺化合物及其制备方法和用途
|
KR20160042039A
(ko)
|
2013-08-09 |
2016-04-18 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
ES2644367T3
(es)
|
2013-08-09 |
2017-11-28 |
Grünenthal GmbH |
Nuevos compuestos de pirimidina condensados sustituidos
|
ES2888074T3
(es)
|
2013-08-16 |
2021-12-30 |
Univ Maastricht |
Tratamiento del deterioro cognitivo con inhibidor de PDE4
|
WO2015063669A1
(en)
|
2013-10-30 |
2015-05-07 |
Wockhardt Limited |
Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
|
SG11201609276RA
(en)
|
2014-05-12 |
2016-12-29 |
Glaxosmithkline Ip No 2 Ltd |
Pharmaceutical compositions comprising danirixin for treating infectious diseases
|
AR101196A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Compuestos de pirimidina sustituidos
|
AR101198A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas como inhibidores de pde4b
|
AR101197A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas
|
CN104130116B
(zh)
*
|
2014-08-18 |
2015-11-11 |
朱丽平 |
一种制备罗氟司特中间体的方法
|
KR101878621B1
(ko)
|
2014-10-24 |
2018-07-13 |
히사미쓰 세이야꾸 가부시키가이샤 |
프로드러그
|
CN104447245B
(zh)
*
|
2014-10-29 |
2017-06-06 |
成都森科制药有限公司 |
罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
|
KR20170034707A
(ko)
|
2015-09-21 |
2017-03-29 |
한미약품 주식회사 |
로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
CN105523954B
(zh)
*
|
2016-02-05 |
2017-07-18 |
徐江平 |
3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
|
US9895359B1
(en)
|
2017-06-07 |
2018-02-20 |
Arcutis, Inc. |
Inhibition of crystal growth of roflumilast
|
US11129818B2
(en)
|
2017-06-07 |
2021-09-28 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast formulation having improved delivery and plasma half life
|
US11534493B2
(en)
|
2017-09-22 |
2022-12-27 |
Arcutis Biotherapeutics, Inc. |
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
|
CA3079299A1
(en)
|
2017-10-23 |
2019-05-02 |
Boehringer Ingelheim International Gmbh |
New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
|
KR20210044191A
(ko)
|
2018-06-04 |
2021-04-22 |
아큐티스, 인크. |
로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
|
EP3972599A1
(en)
|
2019-05-21 |
2022-03-30 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
BR112022015104A2
(pt)
|
2020-01-31 |
2022-09-27 |
Arcutis Biotherapeutics Inc |
Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
|
US20230338345A1
(en)
|
2020-04-23 |
2023-10-26 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Drug combination and use thereof
|
CN111777550A
(zh)
*
|
2020-06-01 |
2020-10-16 |
山东希尔康泰药业有限公司 |
罗氟司特结晶性粉末原料药生产制备方法
|
WO2022120213A1
(en)
|
2020-12-04 |
2022-06-09 |
Berk David Reuben |
Topical roflumilast formulation having antifungal properties
|
WO2022156727A1
(zh)
*
|
2021-01-21 |
2022-07-28 |
浙江养生堂天然药物研究所有限公司 |
治疗肿瘤的组合物及方法
|
WO2022169615A1
(en)
|
2021-02-05 |
2022-08-11 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
WO2023129892A1
(en)
|
2021-12-28 |
2023-07-06 |
Arcutis Biotherapeutics, Inc. |
Topical aerosol foams
|
WO2023129215A1
(en)
|
2021-12-28 |
2023-07-06 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast aerosol foams
|
US20240108609A1
(en)
|
2022-09-15 |
2024-04-04 |
Arcutis Biotherapeutics, Inc. |
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
|